Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | EPHX2 | P34913 | 10/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | FAAH | O00519 | 3/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | ACACB | O00763 | 1/20 | 0.40 |
| ▸ | ELANE | P08246 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL601886 | 1.00 | PARP10 (0.45) | PARP10ALDH1A1POLBEPHX2MEN1 | |
| SCHEMBL602162 | 0.87 | EPHX2 (0.57) | PARP10ALDH1A1EPHX2FAAH | |
| SCHEMBL433358 | 0.87 | EPHX2 (0.57) | PARP10ALDH1A1EPHX2FAAH | |
| SCHEMBL14984454 | 0.87 | SMN1; SMN2 (0.49) | PARP10ALDH1A1POLBEPHX2MEN1 | |
| SCHEMBL14984451 | 0.87 | EPHX2 (0.54) | PARP10ALDH1A1POLBEPHX2MEN1 | |
| SCHEMBL601086 | 0.87 | EPHX2 (0.57) | PARP10ALDH1A1EPHX2FAAH | |
| SCHEMBL4285489 | 0.86 | PARP10 (0.58) | PARP10ALDH1A1EPHX2FAAH | |
| SCHEMBL459829 | 0.85 | PARP10 (0.65) | PARP10ALDH1A1POLBEPHX2KMT2A | |
| SCHEMBL459828 | 0.85 | PARP10 (0.65) | PARP10ALDH1A1POLBEPHX2KMT2A | |
| SCHEMBL10188577 | 0.85 | PARP10 (0.47) | PARP10ALDH1A1EPHX2NPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2595970-B1 | DERIVATIVES OF OXADIAZOLE AND PYRIDAZINE, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | SANOFI SA (FR) | 2015-01-07 | — | — | EP | disclosed |
| US-8546391-B2 | Thiadiazole and oxadiazole derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-10-01 | — | — | US | disclosed |
| US-20130137691-A1 | DERIVATIVES OF OXADIAZOLE AND PYRIDAZINE, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | SANOFI (FR) | 2013-05-30 | — | — | US | disclosed |
| US-20120040984-A1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040984-A1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | OXA1L, CYP11B2, CYP11B1 | PARP10 3840/4885ALDH1A1 126/4885POLB 1087/4885 |
| US-20130137691-A1 | DERIVATIVES OF OXADIAZOLE AND PYRIDAZINE, THEIR PREPARATION AND THEIR APPLICATION IN THERAPEUTICS | XDH, NOX3, OXA1L | PARP10 2063/4885ALDH1A1 565/4885POLB 1238/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.